These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092 [TBL] [Abstract][Full Text] [Related]
4. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients. Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996 [TBL] [Abstract][Full Text] [Related]
5. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial). Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM; J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39). Imaz A; Niubó J; Amara A; Khoo S; Ferrer E; Tiraboschi JM; Acerete L; Garcia B; Vila A; Podzamczer D J Neurovirol; 2018 Aug; 24(4):391-397. PubMed ID: 29542028 [TBL] [Abstract][Full Text] [Related]
7. CNS penetration of ART in HIV-infected children. Van den Hof M; Blokhuis C; Cohen S; Scherpbier HJ; Wit FWNM; Pistorius MCM; Kootstra NA; Teunissen CE; Mathot RAA; Pajkrt D J Antimicrob Chemother; 2018 Feb; 73(2):484-489. PubMed ID: 29126299 [TBL] [Abstract][Full Text] [Related]
8. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595 [TBL] [Abstract][Full Text] [Related]
9. Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid". Calcagno A; D'Avolio A; Di Perri G; Bonora S J Acquir Immune Defic Syndr; 2013 Apr; 62(4):e118-9. PubMed ID: 24135736 [No Abstract] [Full Text] [Related]
10. Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid". Cusini A; Ledergerber B; Widmer N; Günthard HF J Acquir Immune Defic Syndr; 2013 Oct; 64(2):e14-5. PubMed ID: 24047974 [No Abstract] [Full Text] [Related]
11. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D; J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. Calcagno A; Simiele M; Alberione MC; Bracchi M; Marinaro L; Ecclesia S; Di Perri G; D'Avolio A; Bonora S Clin Infect Dis; 2015 Jan; 60(2):311-7. PubMed ID: 25281609 [TBL] [Abstract][Full Text] [Related]
13. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. Delille CA; Pruett ST; Marconi VC; Lennox JL; Armstrong WS; Arrendale RF; Sheth AN; Easley KA; Acosta EP; Vunnava A; Ofotokun I J Clin Pharmacol; 2014 Sep; 54(9):1063-71. PubMed ID: 24691856 [TBL] [Abstract][Full Text] [Related]